Alteogen Inc
KOSDAQ:196170

Watchlist Manager
Alteogen Inc Logo
Alteogen Inc
KOSDAQ:196170
Watchlist
Price: 309 000 KRW 4.04% Market Closed
Market Cap: 16.5T KRW
Have any thoughts about
Alteogen Inc?
Write Note

Alteogen Inc
Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Alteogen Inc
Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Alteogen Inc
KOSDAQ:196170
Cash Equivalents
â‚©27B
CAGR 3-Years
15%
CAGR 5-Years
22%
CAGR 10-Years
N/A
Celltrion Inc
KRX:068270
Cash Equivalents
-â‚©440
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
SK Bioscience Co Ltd
KRX:302440
Cash Equivalents
â‚©127B
CAGR 3-Years
72%
CAGR 5-Years
95%
CAGR 10-Years
N/A
Green Cross Corp
KRX:006280
Cash Equivalents
â‚©12.3B
CAGR 3-Years
-59%
CAGR 5-Years
-34%
CAGR 10-Years
-4%
H
Hugel Inc
KOSDAQ:145020
Cash Equivalents
â‚©182.9B
CAGR 3-Years
61%
CAGR 5-Years
4%
CAGR 10-Years
N/A
P
PharmaResearch Co Ltd
KOSDAQ:214450
Cash Equivalents
â‚©2B
CAGR 3-Years
-56%
CAGR 5-Years
-41%
CAGR 10-Years
N/A
No Stocks Found

Alteogen Inc
Glance View

Market Cap
16.4T KRW
Industry
Biotechnology

Alteogen Inc. is a biopharmaceutical company based in South Korea that has carved out a niche in the development of innovative drug delivery systems. Founded in 2005, the company specializes in the creation of biosimilars and biobetters – biologic drugs that improve upon existing therapies. With a strong pipeline aimed at addressing critical unmet medical needs, Alteogen focuses on therapeutic areas such as oncology, autoimmune diseases, and chronic conditions. One of their standout innovations is the proprietary technology for enhanced antibody-drug conjugates, which can significantly improve the efficacy and safety profiles of existing treatments. As the global demand for advanced therapeutics continues to rise, Alteogen presents a compelling story of potential growth driven by scientific innovation. For investors, Alteogen’s strategic partnerships and collaboration with major pharmaceutical companies amplify its growth trajectory. The company is not only positioned to benefit from its proprietary technologies but is also shaping its portfolio to align with the growing market for biosimilars. As competition in the biopharmaceutical space intensifies, Alteogen’s commitment to research and development sets it apart, showcasing its dedication to delivering next-generation medicines. With a robust clinical development pipeline and strong market momentum, Alteogen Inc. represents an intriguing opportunity for investors looking to tap into the evolution of healthcare and the future of targeted therapies.

Intrinsic Value
33 513.79 KRW
Overvaluation 89%
Intrinsic Value
Price

See Also

What is Alteogen Inc's Cash Equivalents?
Cash Equivalents
27B KRW

Based on the financial report for Sep 30, 2024, Alteogen Inc's Cash Equivalents amounts to 27B KRW.

What is Alteogen Inc's Cash Equivalents growth rate?
Cash Equivalents CAGR 5Y
22%

Over the last year, the Cash Equivalents growth was 21%. The average annual Cash Equivalents growth rates for Alteogen Inc have been 15% over the past three years , 22% over the past five years .

Back to Top